Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 million Sep 30, 2024
Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update Sep 9, 2024
Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan Aug 7, 2024
Poxel Provides an Update on Its Financial Position for the Second Quarter and First Half of 2024 and Announces the Rescheduling of Its Annual General Meeting Jul 15, 2024
Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release Apr 29, 2024
